Skip to content

Familial Partial Lipodystrophy Study

Genetic and Metabolic Basis of Familial Partial Lipodystrophy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02858830
Acronym
FPL
Enrollment
12
Registered
2016-08-08
Start date
2016-08-31
Completion date
2017-04-14
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipodystrophy, Familial Partial

Keywords

FPL, adipose tissue, diabetes, dyslipidemia, metabolic, hyperinsulinemia

Brief summary

Studying patients with rare adipose tissue disorders may help the investigators to better understand the pathophysiology of diabetes and dyslipidemia in relation to adiposity, and thus have an enormous impact on public health.

Detailed description

A systematic study of body fat distribution is necessary to better define the phenotypic spectrum of FPL, and to better recognize FPL in patients with Metabolic Syndrome. Similarly, genetic studies in these patients will not only help better characterize the genotype-phenotype relationship, but is also likely to help identify other genes involved in regulation of lipid homeostasis, as some patients may not have any of the known mutations. The Investigators will systematically study mitochondrial protein quality and function under fasting and fed state in relation to intramyocellular and circulating plasma lipid levels, and compare with age, sex and BMI-matched individuals. The Investigators will also study the rate of de-novo protein synthesis to determine if hyperinsulinemia affects both muscle protein anabolism and catabolism.

Interventions

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Clinical diagnosis of lipodystrophy (decreased subcutaneous fat) 2. Family history of lipodystrophy 3. Normal control subject

Exclusion criteria

1. Inability to provide informed consent 2. Hemoglobin \< 10g%

Design outcomes

Primary

MeasureTime frame
Upper body muscle strength measured by chest press dynamometryBefore consumption of a high fat mixed meal
Change in fractional mitochondrial protein synthesis ratesBefore and after consumption of a high fat mixed meal (approximately 4 hours after the meal)
Lower body muscle strength measured by knee extensionBefore consumption of a high fat mixed meal

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026